Dupilumab Reduced Severe Exacerbation Rates and Improved Pre-bronchodilator Fev1 in Patients With Moderate-to-Severe Asthma Regardless of Exacerbation History of 蠅1, 蠅2, or 蠅3 Prior Exacerbations: Liberty Asthma Traverse

C31. BIOLOGICS WANT TO RULE THE (ASTHMA) WORLD Pub Date : 2023-05-01 DOI:10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4742

J. Maspero, J. Corren, C. Katelaris, M. Castro, M.J.C. Humbert, D. Halpin, A. Altincatal, N. Pandit-Abid, X. Soler, A. Radwan, J. Jacob-Nara, Y. Deniz, P. Rowe

引用次数: 0

查看原文本刊更多论文

Dupilumab降低了中度至重度哮喘患者的严重加重率并改善了支气管扩张剂前Fev1，无论其先前的加重史有1、2或3次加重:自由哮喘穿越

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

C31. BIOLOGICS WANT TO RULE THE (ASTHMA) WORLD

自引率

0.00%

发文量